Inactive Instrument
Antibe Therapeutics Inc Stock Toronto S.E.
Stocks
ATE
CA0370251039
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +4.17% | - | - | 11.47M | |
| -1.59% | -3.35% | +52.37% | +93.70% | 69.54B | |
| -1.34% | -0.75% | +48.21% | +91.86% | 64.97B | |
| +0.30% | -0.69% | +52.56% | +10.23% | 26.51B | |
| -2.35% | -5.75% | -12.90% | +448.54% | 25.89B | |
| -8.37% | -12.43% | +2.08% | -16.71% | 25.64B | |
| -0.96% | +10.36% | +283.06% | +436.50% | 20.22B | |
| -0.51% | +0.23% | +35.77% | -18.70% | 19.98B | |
| -1.91% | -4.37% | +13.28% | +535.19% | 15.69B | |
| -1.47% | +0.68% | +45.51% | +143.08% | 13.49B | |
| Average | -1.82% | -1.93% | +57.77% | +191.52% | 31.33B | |
| Weighted average by Cap. | -1.93% | -1.50% | +53.73% | +151.51% |
Employees
-
